Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bemer-Melchior, P.
Right arrow Articles by Drugeon, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bemer-Melchior, P.
Right arrow Articles by Drugeon, H. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2000) 46, 571-576
© 2000 The British Society for Antimicrobial Chemotherapy

Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex

Pascale Bemer-Melchiora,*, André Bryskierb and Henri B. Drugeona

a Department of Microbiology, Laënnec University Hospital, Laënnec University Hospital, Bd J. Monod, 44093 Saint-Herblain cedex 1, Nantes, France; b Clinical Pharmacology of Anti-infectious Agents, Hoechst Marion Roussel, Romainville, France

The in vitro activity of rifapentine for 44 clinical isolates of Mycobacterium tuberculosis complex was compared with that of rifampicin using the Bactec radiometric method and the absolute concentration method for susceptibility testing. Twenty-nine M. tuberculosis, 11 Mycobacterium bovis and four Mycobacterium africanum strains were studied. Control tests showed that rifapentine was stable for 14 days in 7H9 broth and for 3 weeks in 7H10 agar medium. The 44 M. tuberculosis complex strains were more susceptible to rifapentine than to rifampicin, irrespective of the testing method. In the radiometric system, the MIC50 and MIC90 of rifapentine for M. tuberculosis complex strains were one or two two-fold dilutions lower than those of rifampicin (0.06–0.125 mg/L versus 0.25 mg/L, respectively). By the absolute concentration method, the MIC50 and MIC90 of rifapentine for M. tuberculosis complex strains were two two-fold dilutions lower than those of rifampicin (0.125–0.25 mg/L versus 0.5–1 mg/L, respectively). The MIC90 of rifapentine for the 44 M. tuberculosis complex strains was always 0.25 mg/L, irrespective of the method used, but the radiometric method was more reliable and more reproducible than the agar 7H10 method.

* Corresponding author. Tel: +33-2-40-16-54-66; Fax: +33-2-40-16-54-55; E-mail: pascale.bemermelchior{at}chu-nantes.fr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
M. Y. Krishnan, E. J. B. Manning, and M. T. Collins
Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs
J. Antimicrob. Chemother., August 1, 2009; 64(2): 310 - 316.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. van den Boogaard, G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse
New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 849 - 862.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.